Stocks Health care SGMT
NASDAQ · Health careSagimet Biosciences Inc. (SGMT)
It posted a net loss of $47.1M. At June 30, 2026 it held $165.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Sagimet Biosciences Inc. does
Sagimet Biosciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SGMT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$51M | -$1.58 | n/a |
| 2024 | n/a | -$45.6M | -$1.45 | n/a |
| 2023 | $2M | -$27.9M | -$2.66 | n/a |
| 2023 | n/a | -$30.5M | -$165.20 | n/a |
Latest SEC filings
What Sagimet Biosciences Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Other event 8-K
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- July 21, 2026
- June 12, 2026
- June 3, 2026
- May 12, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about SGMT
What does Sagimet Biosciences Inc. do?
Sagimet Biosciences Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SGMT.
Is Sagimet Biosciences Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $47.1M.
When did Sagimet Biosciences Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 17, 2026.
Similar companies
Follow SGMT
Get an email when Sagimet Biosciences Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SGMT: get an email when it filesWhere the numbers come from
Financial figures are the values Sagimet Biosciences Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.